Sanaria Inc.
24Patents
23Active
24Granted
47Portfolio score
Filing activity: Oct 4, 2004 → Dec 7, 2023 · 3 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8043625B2 | Purified plasmodium and vaccine compositions | Emerging Cross-Sectional Technologies | 19 | Active |
| US7229627B2 | Apparatuses and methods for the production of haematophagous organisms and parasites suitable for vaccine production | Emerging Cross-Sectional Technologies | 18 | Expired |
| US8367810B2 | Purified plasmodium and vaccine compositions | Emerging Cross-Sectional Technologies | 17 | Active |
| US8992944B2 | Purified Plasmodium and vaccine composition | Emerging Cross-Sectional Technologies | 13 | Active |
| US8821896B2 | Purified Plasmodium and vaccine composition | Emerging Cross-Sectional Technologies | 11 | Active |
| US9241982B2 | Purified plasmodium and vaccine compositions | Emerging Cross-Sectional Technologies | 11 | Active |
| US8802919B2 | Apparatuses and methods for the production of haematophagous organisms and parasites suitable for vaccine production | Emerging Cross-Sectional Technologies | 11 | Active |
| US9278125B2 | Pharmaceutical compositions comprising attenuated Plasmodium sporozoites and glycolipid adjuvants | Emerging Cross-Sectional Technologies | 7 | Active |
| US9616115B2 | Purified plasmodium and vaccine compositions | Emerging Cross-Sectional Technologies | 6 | Active |
| US9878026B2 | Infectious plasmodium sporozoites grown in vitro | Emerging Cross-Sectional Technologies | 5 | Active |
| US9642909B2 | Pharmaceutical compositions comprising attenuated Plasmodium sporozoites and glycolipid adjuvants | Emerging Cross-Sectional Technologies | 4 | Active |
| US10995980B2 | Cryovial storage system | Mechanical Engineering; Lighting; Heating | 4 | Active |
| US10441646B2 | Infectious plasmodium sporozoites grown in vitro | Emerging Cross-Sectional Technologies | 3 | Active |
| US10272146B2 | Purified plasmodium and vaccine compositions | Emerging Cross-Sectional Technologies | 3 | Active |
| US11883475B2 | Infectious Plasmodium sporozoites grown in vitro | Emerging Cross-Sectional Technologies | 1 | Active |
| US11207395B2 | Infectious plasmodium sporozoites grown in vitro | Emerging Cross-Sectional Technologies | 1 | Active |
| US11503819B2 | Apparatus and method of use for an automated mosquito salivary gland extraction device | Emerging Cross-Sectional Technologies | 1 | Active |
| US12409213B2 | Live attenuated oral vaccine against shigellosis and typhoid fever | Emerging Cross-Sectional Technologies | 0 | Active |
| US12171822B2 | Infectious plasmodium sporozoites grown in vitro | Emerging Cross-Sectional Technologies | 0 | Active |
| US11021535B2 | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use | Emerging Cross-Sectional Technologies | 0 | Active |
| US9931389B2 | Genetic attenuation of plasmodium by B9 gene disruption | Emerging Cross-Sectional Technologies | 0 | Active |
| US11760794B2 | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use | Emerging Cross-Sectional Technologies | 0 | Active |
| US10781419B2 | Mosquito salivary gland extraction device and methods of use | Emerging Cross-Sectional Technologies | 0 | Active |
| US10197577B2 | Serum antibody assay for determining protection from malaria, and pre-erythrocytic subunit vaccines | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.